What drove the pre-market fall in OBSN.SW stock today?

The pre-market fall reflects a mix of thin liquidity, concentrated selling, and pipeline uncertainty. Volume spiked to **2,351,202**, and no offsetting capital or licensing news was posted on the company site.

What is Meyka AI's rating for OBSN.SW stock?

Meyka AI rates OBSN.SW with a score of **62.59/100**, Grade **B**, suggestion **HOLD**. The grade balances sector comparison, key metrics, growth and analyst signals.

Does ObsEva pay dividends and what are key financial risks?

ObsEva pays no dividend. Key financial risks include ongoing negative EPS, cash burn, and potential dilution from future financing rounds needed to advance clinical programs.

What short-term price range should traders consider for OBSN.SW stock?

For short-term planning use a conservative range: downside **CHF0.0005** and upside **CHF0.0030**. High volatility and low liquidity mean large orders can move the price materially.

CH Stocks

OBSN.SW ObsEva S.A. (SIX) CHF0.0012 pre-market 13 Mar 2026: heavy volume noted

ByDanny Kontos March 13, 2026March 13, 2026

ObsEva S.A. (OBSN.SW) trades at CHF0.0012 pre-market on 13 Mar 2026 after a one-day drop of -76.92%, making OBSN.SW stock one of the most active names on the SIX exchange. The surge in activity shows 2,351,202 shares traded versus an average volume of 675,842, and a wide intraday range between CHF0.0012 and CHF0.0058. Investors are watching liquidity, clinical pipeline updates, and cash runway as drivers of price moves in this small-cap biotech.